ACM  >> Vol. 5 No. 1 (March 2015)

    感染性休克综合性治疗的研究进展
    The Research Progress of the Comprehensive Treatment of Septic Shock

  • 全文下载: PDF(405KB) HTML   XML   PP.1-6   DOI: 10.12677/ACM.2015.51001  
  • 下载量: 1,721  浏览量: 6,564  

作者:  

杨 晶:内蒙古医科大学,内蒙古 呼和浩特;
崔晓迎:内蒙古医科大学附属医院急诊内科,内蒙古 呼和浩特

关键词:
感染性休克治疗中医药治疗Septic Shock Treatment Traditional Chinese Medicine Treatment

摘要:

感染性休克是一种常见的综合征,近年来其发生几率逐年增高,病死率居高不下,越来越多的医务工作者及学者开始关注其发生、发展及诊断治疗情况,期望其规范化的治疗以降低其病死率。本文就近年来感染性休克的治疗进展进行综述。

Septic shock is a common syndrome. In recent years, the incidence of septic shock increases year by year, and the mortality rate of septic shock is high. More and more medical workers and scholars begin to pay attention to septic shock’s occurrence, development, diagnosis and treatment, expecting the standardized treatment to reduce the mortality. The current review is to update the management of sepsis and septic shock.

文章引用:
杨晶, 崔晓迎. 感染性休克综合性治疗的研究进展[J]. 临床医学进展, 2015, 5(1): 1-6. http://dx.doi.org/10.12677/ACM.2015.51001

参考文献

[1] Dellinger, R.P., Levy, M.M., Rhodes, A., et al. (2013) The surviving sepsis campaign guidelines committee including the pediatric subgroup. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. Critical Care Medicine, 41, 580-637.
[2] 刘宇, 周荣斌 (2013) 感染性休克. 急诊内科学. 第3版, 人民卫生出版社, 北京, 133-140.
[3] Batzofin, B.M., Sprung, C.L. and Weiss, Y.G. (2011) The use of steroids in the treatment of severe sepsis and septic shock. Best Practice & Research Clinical Endocrinology & Metabolism, 25, 735-743.
[4] Robingon, K., Kruger, P., Prins, J., et al. (2011) The metabolic syndrome in critically ill patients. Best Practice & Research Clinical Endocrinology & Metabolism, 25, 835-845.
[5] Galley, H.F. (2011) Oxidative stress and mitochondrial dysfunction in sepsis. British Journal of Anaesthesia, 107, 57-64.
[6] Martin, G.S. (2012) Sepsis, severe sepsis and septic shock: Changes in incidence, pathogens and outcomes. Expert Review of Anti-Infective Therapy, 10, 701-706.
[7] 刘宇, 周荣斌 (2013) 感染性休克. 急诊内科学. 第3版, 人民卫生出版社, 北京, 123-129.
[8] 伊明, 沈洪 (2012) 抗感染性休克治疗的认识还在争议中. 中国危重症急救医学, 24, 10-12.
[9] 徐静媛, 刘玲, 邱海波 (2011) 液体复苏对感染性休克患者继发肺水肿的影响. 国际麻醉学与复苏杂志, 32, 198- 200.
[10] Hang, W.P., Jiang, W.Q., Hu, B., et al. (2012) Significance of serum procalcitonin levels in the evaluation of severity and prognosis of patients with systemic inflammatory response syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 24, 294-297.
[11] Giamarellos-Bourboulis, E.J., Tsangaris, I., Kanni, T., Mouktaroudi, M., Pantelidou, I., Adamis, G., et al. (2011) Procalcitonin as an early indicator of outcome in sepsis: A prospective observational study. Journal of Hospital Infection, 77, 58-63.
[12] Azevedo, J.R., Torres, O.J., Czeczko, N.G., Tuon, F.F., Nassif, P.A. and Souza, G.D. (2012) Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. Revista do Colégio Brasileiro de Cirurgiões, 39, 456-461.
[13] Kumar, A., Roberts, D., Wood, K.E., Light, B., Parrillo, J.E., Sharma, S., et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine, 34, 1589-1596.
[14] 徐腾达 (2010) 休克. In: 于学忠, Ed., 协和急诊医学, 科学出版社, 北京, 88-94.
[15] Rivers, E., Nguyen, B., Havstad, S., Ressler, J., Muzzin, A., Knoblich, B., et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. The New England Journal of Medicine, 345, 1368-1377.
[16] 吴先龙 (2013) 严重脓毒症早期应用集束化治疗的依从性及对病死率的影响. 中国呼吸与危重监护杂志, 1, 92- 93.
[17] Dellinger, R.P., Levy, M.M., Rhodes, A., Annane, D., Gerlach, H., Opal, S.M., et al. (2013) Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Medicine, 39, 165- 228.
[18] 张志忠, 张伟珏, 周荣斌 (2010) B型脑钠肽对脓毒性休克患者的诊断及预后评估价值. 中国全科医学, 13, 1320.
[19] 刘志永, 朱红, 马晓春 (2014) 肝素治疗脓毒症的系统评价. 中华危重病急救医学, 3, 135-141.
[20] Li, X., Zheng, Z., Mao, Y. and Ma, X. (2012) Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: A preliminary study on the roles of angiopoietin/Tie2 axis. Thrombosis Research, 129, e223-e228.
[21] Mu, E., Ding, R., An, X., Li, X., Chen, S. and Ma, X. (2012) Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-β/Smad signaling pathway. Thrombosis Research, 129, 479-485.
[22] Ding, R., Zhao, D., Guo, R., Zhang, Z. and Ma, X. (2011) Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thrombosis Research, 128, e160-e165.
[23] Zhao, D., Ding, R., Mao, Y., Wang, L., Zhang, Z. and Ma, X. (2012) Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses. Inflammation, 35, 1825-1832.
[24] 占志刚, 李春盛 (2012) D-二聚体对急诊脓毒症患者预后价值的前瞻性研究. 中国危重病急救医学, 3, 135-139.
[25] 赵永祯, 李春盛 (2014) 生物标志物组合对急诊脓毒症和重度脓毒症患者的诊断价值. 中华危重病急救医学, 3, 153-158.
[26] 刘朝晖, 苏磊, 廖银光, 刘志锋, 刘俊灵 (2014) 尿毒症患者营养目标摄入对临床预后影响的前瞻性随机对照研究. 中华危重病急救医学, 3, 131-134.
[27] 肖桂珍, 苏磊, 段鹏凯, 王钦先, 黄英 (2011) 间接测热法与传统能量估算法测定重症监护病房患者能量消耗的比较. 中国危重病急救医学, 7, 392-395.
[28] 奚肇庆, 张劲松, 芮庆林, 谢康民, 王一镗 (2010) 严重脓毒症与感染性休克中西医结合治疗指南解读. 公共卫生与临床医学, 2, 87-96.
[29] 郑喜胜, 秦根生, 董照刚, 冯永利 (2013) 血必净注射液对感染性休克患者PCT、CRP的影响. 中国实用医药, 17, 135-136.
[30] 巴特金, 苏和, 张松波, 莫日根图, 张瑞芬, 李娟 (2010) 蒙药斯日西散预防脓毒症患者肠内营养胃肠道并发症的疗效观察. 中国药物与临床, 3, 358.